Literature DB >> 12364937

Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis.

Marco Aurélio Lana-Peixoto1, Antônio Lúcio Teixeira, Vitor Geraldi Haase.   

Abstract

Depression and suicide have been reported in association with multiple sclerosis (MS). Some studies show that interferon beta may increase the depression rate. We report a case of depression and suicidal ideation in coincidence with the start of increased doses of interferon beta-1a and their complete reversal following the drug withdrawal. The patient was a 21-year-old man with MS and no past history of affective disorders who was given interferon beta-1a in the dose of 11 microgram three times per week. As a new relapse occurred the dose of interferon beta-1a was increased to 22 microgram three times a week. The patient then observed increased worry, irritability and a sense of discouragement as well as recurring suicidal thoughts. His mood was rapidly restored following interferon beta-1a withdrawal. This case suggests that patients with MS may develop depression and suicidal thoughts when treated with high doses of interferon beta-1a.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364937     DOI: 10.1590/s0004-282x2002000500007

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  6 in total

Review 1.  Exercise and multiple sclerosis.

Authors:  Lesley J White; Rudolph H Dressendorfer
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 2.  Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment.

Authors:  Claudio Solaro; Giulia Gamberini; Fabio Giuseppe Masuccio
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

3.  Elevated cytokine expression in the orbitofrontal cortex of victims of suicide.

Authors:  L H Tonelli; J Stiller; D Rujescu; I Giegling; B Schneider; K Maurer; A Schnabel; H-J Möller; H H Chen; T T Postolache
Journal:  Acta Psychiatr Scand       Date:  2007-12-13       Impact factor: 6.392

4.  Psychiatric side effects of medications prescribed in internal medicine.

Authors:  Rodrigo Casagrande Tango
Journal:  Dialogues Clin Neurosci       Date:  2003-06       Impact factor: 5.986

5.  Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.

Authors:  Sven Schippling; Paul O'Connor; Volker Knappertz; Christoph Pohl; Timon Bogumil; Gustavo Suarez; Stuart Cook; Massimo Filippi; Hans-Peter Hartung; Giancarlo Comi; Douglas R Jeffery; Ludwig Kappos; Douglas S Goodin; Barry Arnason
Journal:  J Neurol       Date:  2016-05-13       Impact factor: 4.849

6.  Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort.

Authors:  Tristan Römer; Sabrina Franzen; Hanna Kravets; Ahmed Farrag; Anna Makowska; Hans Christiansen; Michael J Eble; Beate Timmermann; Gundula Staatz; Felix M Mottaghy; Martina Bührlen; Ulrich Hagenah; Alexander Puzik; Pablo Hernáiz Driever; Jeanette Greiner; Norbert Jorch; Stephan Tippelt; Dominik T Schneider; Gabriele Kropshofer; Tobias R Overbeck; Holger Christiansen; Triantafyllia Brozou; Gabriele Escherich; Martina Becker; Waltraud Friesenbichler; Tobias Feuchtinger; Wolfram Puppe; Nicole Heussen; Ralf D Hilgers; Udo Kontny
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.